Find recruiting clinical trials for glioblastoma (GBM) in the UK � from maximal safe resection to temozolomide, tumour-treating fields and emerging immunotherapies. See where trials fit into your treatment pathway.
Free to use � Live data from ClinicalTrials.gov � Updated daily
Answer a few questions about your condition and we'll match you to the most relevant clinical trials.
See where clinical trials fit into your treatment journey
Surgery to remove as much tumour as safely possible, often guided by brain mapping
Standard: Awake craniotomy with intraoperative MRI and fluorescence guidance (5-ALA) where available
The gold standard first-line treatment since 2005 � concurrent and adjuvant chemotherapy with radiotherapy
Standard: 60 Gy radiotherapy over 6 weeks with daily temozolomide, then 6-12 cycles adjuvant temozolomide
Wearable device delivering alternating electric fields to disrupt cancer cell division
Standard: Optune device worn =18 hours/day alongside temozolomide � approved but not yet widely available on NHS
At recurrence, trials explore dendritic cell vaccines, CAR-T, oncolytic viruses, and targeted agents
Emerging: Dendritic cell vaccines (ICT-107), oncolytic viruses (G207), CAR-T targeting EGFRvIII, and IDH-targeted therapy for secondary GBM
Glioblastoma (GBM) is the most common and aggressive primary brain tumour in adults, with about 3,200 new cases per year in the UK. Symptoms include headaches, seizures, cognitive changes, and weakness. It grows rapidly and diffusely infiltrates brain tissue, making complete surgical removal impossible.
Median survival for GBM is only 15-18 months with standard treatment. Fewer than 10% of patients survive 5 years. Trials are critical � every major advance in GBM treatment came from clinical research. The blood-brain barrier makes drug delivery challenging, making novel approaches (viral therapy, immunotherapy, convection-enhanced delivery) especially important.
MGMT promoter methylation status is the most important biomarker in GBM. Patients with methylated MGMT respond better to temozolomide (median survival 24+ months vs 14 months). IDH mutation, if present, indicates secondary GBM with a somewhat better prognosis. Ask your neuro-oncologist about molecular testing.
Loading trials from ClinicalTrials.gov...
Active research areas include tumour-treating fields (Optune), CAR-T cell therapy, oncolytic viruses, immunotherapy combinations, targeted therapies for IDH mutations, and blood-brain barrier disruption techniques.
Yes. Some trials enrol patients immediately after surgery, testing new adjuvant or neoadjuvant approaches. The timing depends on the trial design — early discussion with your neuro-oncologist is important.
IDH mutations occur in some gliomas and respond differently to treatment. IDH-mutant glioblastoma has specific targeted therapy trials. Genetic testing of your tumour helps determine which trials you may be eligible for.
Use our search above to find trials that match your condition and location. Review the eligibility criteria carefully.
Talk to your GP or specialist about any trials you are interested in. They can help determine if a trial is appropriate for you.
Reach out to the trial team directly using the contact information on the ClinicalTrials.gov listing. They will guide you through screening.
If you meet the criteria and decide to participate, you will go through informed consent and begin the trial process.